PHIO - Phio Pharmaceuticals Corp.

1.19
-0.040   -3.361%

Share volume: 230,505
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.23
-0.04
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 6%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.80%
1 Month
-5.56%
3 Months
14.42%
6 Months
-44.96%
1 Year
-44.39%
2 Year
74.49%
Key data
Stock price
$1.19
P/E Ratio 
N/A
DAY RANGE
$1.18 - $1.24
EPS 
-$1.70
52 WEEK RANGE
$0.81 - $4.19
52 WEEK CHANGE
-$44.39
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
11.617 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
3.85
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$133,528
AVERAGE 30 VOLUME 
$185,568
Company detail
CEO: Geert C. PhD
Region: US
Website: phiopharma.com
Employees: 10
IPO year: 2010
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT) PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression.

Recent news